Marinus制药 MRNS 深 沪
已收盘 07-26 16:00:00 美东时间
1.43
+0.015
+1.06%
华盛通- 最 高1.47
- 今 开1.43
- 成交量 17.57万股
- 最 低 1.41
- 昨 收 1.415
- 总市值 7807.80万
- 52周最高 11.26
- 市盈率 静 --
- 换手率 0.32%
- 52周最低 1.10
- 委 比 -16.17%
- 总股本 5460.00万
- 历史最高 82.88
- 量 比 0.42
- 振 幅 4.24%
- 历史最低 1.10
- 每 手 1
- 风险率 3.38%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Class Action Lawsuit against Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS)
A class action lawsuit was filed against Marinus Pharmaceuticals, Inc. ($MRNS) ...
07-22 15:23
新浪财经ESG：MRNS 路孚特（Refinitiv）ESG评级调升至C-
新浪财经ESG评级中心提供包括资讯、报告、培训、咨询等在内的14项ESG服务，助力上市公司传播ESG理念，提升ESG可持续发展表现。点击查看【 ESG评级中...
07-08 07:00
Truist Securities Maintains Buy on Marinus Pharma, Maintains $10 Price Target
Truist Securities analyst Joon Lee maintains Marinus Pharma (NASDAQ:MRNS) with a Buy and maintains $10 price target.
06-19 01:49
Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME), PolyPid (PYPD) and Marinus (MRNS)
Analysts have been eager to weigh in on the Healthcare sector with new ratings ...
06-18 18:20
快讯 | Marinus Pharmaceuticals公司：临床试验完成了第一个共同主要终点。
Marinus Pharmaceuticals Inc: Raise Trial Met Its First Co-Primary Endpoint
06-17 19:00
快讯 | Marinus Pharmaceuticals未能在第二次共同主要终点获得统计学意义。
Marinus Pharmaceuticals Inc: Failed to Achieve Statistical Significance on Seco...
06-17 19:00
快讯 | Marinus Pharmaceuticals公司: 预计现金流可以支撑到2025年第二季度
Marinus Pharmaceuticals Inc: Projects Cash Runway Into Q2 2025
06-17 19:00
值得重新审视！华尔街大佬Cantor Fitzgerald：这14只生物科技股被低估了
美国知名金融服务公司Cantor Fitzgerald在最近发布的一份报告中挑选了14只生物科技股，并认为这些股票被严重低估，值得“重新审视”。
05-13 14:43
Cantor picks 14 undervalued biotech stocks worth a second look
Cantor Fitzgerald has selected its 14 top picks for biotech stocks that it regards as significantly undervalued and worth a "fresh" look. All of the picks were down more than 20% year-to-date, as of M...
05-12 23:00
Buy Rating Affirmed for Marinus Pharmaceuticals Amid Positive Sales and Promising Drug Trials
In a report released today, Jason Butler from JMP Securities reiterated a Buy r...
05-09 00:15
